| abstract |
A bleeding-reducing agent for use in a cerebrovascular disorder which comprises a poly(ADP-ribose)polymerase inhibitor (PARP inhibitor). The PARP inhibitor has an effect of preventing a vascular endothelial cell disorder, and therefore can reduce bleeding in a cerebrovascular disorder. When used in combination with a thrombolytic agent, the PARP inhibitor can prevent bleeding which is a matter of concern in the use of a thrombolytic agent, and an effect of prolonging the therapeutic time window of the thrombolytic agent can also be expected. Further, the PARP inhibitor does not affect the blood coagulation system and the fibrinolytic system, and therefore can serve as a safe bleeding-reducing agent which produces little adverse side effects. |